Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Non-Myeloablative Trial With 90Y-Humanized MN-14 (Anti-CEA) Antibody for Relapsed or Refractory Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00006458 is registered in ClinicalTrials.gov with Garden State Cancer Center at the Center for Molecular Medicine and Immunology as lead sponsor.

NCT NCT00006458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00006458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Non-Myeloablative Trial With 90Y-Humanized MN-14 (Anti-CEA) Antibody for Relapsed or Refractory Advanced Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Phase
Phase 1
Overall status
Unknown status
Start date
August 31, 2000
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer